Now Accepting Public Comments through June 8, 2026 on the Draft 2027 CMS QRDA III Implementation Guide, Schematron, and Sample File for Eligible Clinicians
Top
Official websites use
.gov
A .gov website belongs to an official government organization in the United States.
Secure
.gov
websites use HTTPS
A
lock
(
)
or
https://
means you’ve safely connected to the
.gov
website. Share sensitive information only on official, secure websites.
["Allergy, Intolerance": "Beta Blocker Therapy Ingredient"]
Performance/Reporting Period
2025
Value Set Description from VSAC
Clinical Focus: The purpose of this value set is to represent concepts for medications containing ingredients for beta blocker therapy.
Data Element Scope: This value set may use a model element related to Allergy/Intolerance.
Inclusion Criteria: Includes concepts that represent an allergy or intolerance for prescribable beta blockers.
Exclusion Criteria: No exclusions.
Data Element Scope: This value set may use a model element related to Allergy/Intolerance.
Inclusion Criteria: Includes concepts that represent an allergy or intolerance for prescribable beta blockers.
Exclusion Criteria: No exclusions.
Constrained to codes in the Beta Blocker Therapy Ingredient value set (2.16.840.1.113883.3.526.3.1493)
QDM Datatype and Definition
"Allergy Intolerance"
Data elements that meet criteria using this datatype should document the allergy or intolerance and its corresponding value set.
Timing:
- The prevalencePeriod references the time from the onset date to the abatement date. Often an abatement date is not present as allergy or intolerance is ongoing.
- The author dateTime references the recorded time.
eCQMs using this data element:
Last Updated: Jun 26, 2024